Australian and New Zealand Intensive Care Research Centre, Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Department of Intensive Care Medicine, The Queen Elizabeth Hospital, University of Adelaide, Adelaide, SA, Australia.
Crit Care Med. 2019 Jun;47(6):765-773. doi: 10.1097/CCM.0000000000003762.
To examine long-term survival and quality of life of patients with early septic shock.
Prospective, randomized, parallel-group trial.
Fifty-one hospitals in Australia, New Zealand, Finland, Hong Kong, and the Republic of Ireland.
One-thousand five-hundred ninety-one patients who presented to the emergency department with early septic shock between October 2008 and April 2014, and were enrolled in the Australasian Resuscitation in Sepsis Evaluation trial.
Early goal-directed therapy versus usual care.
Long-term survival was measured up to 12 months postrandomization. Health-related quality of life was measured using the EuroQoL-5D-3L, Short Form 36 and Assessment of Quality of Life 4D at baseline, and at 6 and 12 months following randomization. Mortality data were available for 1,548 patients (97.3%) and 1,515 patients (95.2%) at 6 and 12 months, respectively. Health-related quality of life data were available for 85.1% of survivors at 12 months. There were no significant differences in mortality between groups at either 6 months (early goal-directed therapy 21.8% vs usual care 22.6%; p = 0.70) or 12 months (early goal-directed therapy 26.4% vs usual care 27.9%; p = 0.50). There were no group differences in health-related quality of life at either 6 or 12 months (EuroQoL-5D-3L utility scores at 12 mo early goal-directed therapy 0.65 ± 0.33 vs usual care 0.64 ± 0.34; p = 0.50), with the health-related quality of life of both groups being significantly lower than population norms.
In patients presenting to the emergency department with early septic shock, early goal-directed therapy compared with usual care did not reduce mortality nor improve health-related quality of life at either 6 or 12 months.
研究早期脓毒性休克患者的长期生存和生活质量。
前瞻性、随机、平行组试验。
澳大利亚、新西兰、芬兰、中国香港和爱尔兰共和国的 51 家医院。
2008 年 10 月至 2014 年 4 月期间因早期脓毒性休克就诊于急诊科的 1591 例患者,他们参加了澳大利亚复苏脓毒症评估试验。
早期目标导向治疗与常规治疗。
长期生存在随机分组后 12 个月内进行测量。使用 EuroQoL-5D-3L、36 项简短健康状况调查和 4D 生活质量评估在基线时以及随机分组后 6 个月和 12 个月测量健康相关生活质量。在 6 个月和 12 个月时,分别有 1548 例患者(97.3%)和 1515 例患者(95.2%)可获得死亡率数据。在 12 个月时,85.1%的幸存者可获得健康相关生活质量数据。两组在 6 个月(早期目标导向治疗组 21.8%比常规治疗组 22.6%;p=0.70)或 12 个月(早期目标导向治疗组 26.4%比常规治疗组 27.9%;p=0.50)时的死亡率均无显著差异。两组在 6 个月或 12 个月时的健康相关生活质量均无差异(12 个月时的 EuroQoL-5D-3L 效用评分:早期目标导向治疗组 0.65±0.33 比常规治疗组 0.64±0.34;p=0.50),且两组的健康相关生活质量均显著低于人群正常值。
在因早期脓毒性休克就诊于急诊科的患者中,与常规治疗相比,早期目标导向治疗并未降低死亡率或改善 6 个月或 12 个月时的健康相关生活质量。